- Home
- SIGI vs BLCO Comparison
SIGI vs BLCO Comparison
Compare SIGI & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGI
- BLCO
- Stock Information
- Founded
- SIGI 1926
- BLCO 1853
- Country
- SIGI United States
- BLCO Canada
- Employees
- SIGI N/A
- BLCO N/A
- Industry
- SIGI Property-Casualty Insurers
- BLCO Ophthalmic Goods
- Sector
- SIGI Finance
- BLCO Health Care
- Exchange
- SIGI Nasdaq
- BLCO Nasdaq
- Market Cap
- SIGI 5.2B
- BLCO 4.4B
- IPO Year
- SIGI N/A
- BLCO 2022
- Fundamental
- Price
- SIGI $87.43
- BLCO $13.45
- Analyst Decision
- SIGI Hold
- BLCO Hold
- Analyst Count
- SIGI 8
- BLCO 13
- Target Price
- SIGI $94.00
- BLCO $15.63
- AVG Volume (30 Days)
- SIGI 344.8K
- BLCO 717.1K
- Earning Date
- SIGI 07-17-2025
- BLCO 07-30-2025
- Dividend Yield
- SIGI 1.74%
- BLCO N/A
- EPS Growth
- SIGI N/A
- BLCO N/A
- EPS
- SIGI 3.68
- BLCO N/A
- Revenue
- SIGI $4,981,891,000.00
- BLCO $4,829,000,000.00
- Revenue This Year
- SIGI $6.05
- BLCO $6.97
- Revenue Next Year
- SIGI $7.43
- BLCO $5.48
- P/E Ratio
- SIGI $23.72
- BLCO N/A
- Revenue Growth
- SIGI 13.30
- BLCO 11.94
- 52 Week Low
- SIGI $78.13
- BLCO $10.45
- 52 Week High
- SIGI $103.56
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- SIGI 51.12
- BLCO 69.62
- Support Level
- SIGI $84.24
- BLCO $12.02
- Resistance Level
- SIGI $86.95
- BLCO $12.31
- Average True Range (ATR)
- SIGI 1.54
- BLCO 0.45
- MACD
- SIGI 0.18
- BLCO 0.15
- Stochastic Oscillator
- SIGI 73.06
- BLCO 88.94
About SIGI Selective Insurance Group Inc.
Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. The Company has four operating segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, Investments. Majority of revenue is gained from Standard Personal Lines. Currently company has it's revenues from States of USA and Columbia.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.